Find information on thousands of medical conditions and prescription drugs.

Viadur

Leuprolide is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, it intially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat precocious puberty, and to control ovarian stimulation in IVF. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals under the brand name Lupron.

Read more at Wikipedia.org


[List your site here Free!]


Alza Corp. to acquire Crescendo Pharmaceuticals for 41.67 times revenue, The
From Weekly Corporate Growth Report, 10/16/00

The Deal: The Alza Corp has announced that it has exercised its option to purchase the Crescendo Pharmaceuticals Corp. for $100 million in cash. Crescendo, a former unit of Alza, was used to finance research and development through outside investors.

Discussion: The Crescendo Pharmaceuticals Corp. is a development-stage firm that received $300 million from its parent to fund the research of certain drug candidates. Crescendo now pays ALZA from these funds to develop these products, many of which use ALZA's drug-delivery technologies. The firm is currently paying ALZA to develop a treatment for acute and chronic pain. ALZA is marketing three Crescendo-funded, FDA-approved drugs: Ditropan, a treatment for overactive bladder; Concerta, a hyperactivity treatment; and Viadur, a prostate cancer therapy.

The Alza Corp. designs controlled-dosage drug-delivery systems, which range from skin patches to low-current electric devices that administer drugs through the skin. Key drugs that use ALZA's technology include Procardia XL oral angina/hypertension treatment; No. 1 smoking cessation patch NicoDerm CQ; and over-the-counter allergy medication Sudafed 24. ALZA also develops drugs for its own account, including Ditropan XL for overactive bladder and cancer treatment Doxil.

Copyright NVST.com, Inc. Oct 16, 2000
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Viadur
Home Contact Resources Exchange Links ebay